

# **Global Human Growth Hormone Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023**

<https://marketpublishers.com/r/G33C1CDAF3FEN.html>

Date: April 2018

Pages: 130

Price: US\$ 1,800.00 (Single User License)

ID: G33C1CDAF3FEN

## **Abstracts**

### **EXECUTIVE SUMMARY**

The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogenmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.

The report titled “Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” also analyzes the overall sizing, growth and forecast of Growth

## Hormone Deficiency Drugs Market for the global market.

Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.

The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 – 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.

### **SCOPE OF THE REPORT**

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment – TransCon-hGH, Somapacitan, Somavaratan, Somatrogen (Forecast Period: 2020-2023)

Market Potential

Clinical Trials

Product Description

Regulatory Phases

7Ps Analysis

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market – Sizing and Growth

Actual Period: 2013-2017

Forecast Period: 2018-2023

Regional Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market –  
Sizing and Growth: North America, Europe, Rest of the World

Actual Period: 2013-2017

Forecast Period: 2018-2023

Country Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market –  
Sizing and Growth: US, UK, France, Spain, Germany, Japan

Actual Period: 2013-2017

Forecast Period: 2018-2023

Other Report Highlights

Company Analysis – Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc.,  
Opko Health Inc., Pfizer Inc.

## **CUSTOMIZATION OF THE REPORT**

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

## Contents

### **1. RESEARCH METHODOLOGY**

### **2. EXECUTIVE SUMMARY**

### **3. GROWTH HORMONE DEFICIENCY DRUGS PRODUCT - AN OVERVIEW**

- 3.1. Growth Hormone (GH) and its Function
- 3.2. Growth Hormone Deficiency (GHD) and its Symptoms
- 3.3. Causes of Growth Hormone Deficiency (GHD)

### **4. DIAGNOSIS OF GROWTH HORMONE DEFICIENCY (GHD)**

### **5. TREATMENT OF GROWTH HORMONE DEFICIENCY (GHD)**

### **6. GLOBAL GROWTH HORMONE DRUGS MARKET**

- 6.1. Global Growth Hormone Drugs Market Size, By value, 2013-2017
- 6.2. Global Growth Hormone Drugs Market Size, By value, 2018-2023

### **7. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET**

- 7.1. Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017
- 7.2. Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023

### **8. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET, BY END USER**

- 8.1. Global Growth Hormone Deficiency Drugs Market, By End User: Break down (%)
  - 8.1.1. Global Growth Hormone Deficiency Drugs Market, By End User: 2017%
  - 8.1.2. Global Growth Hormone Deficiency Drugs Market, By End User: 2023%
- 8.2. Global Growth Hormone Deficiency Drugs Market, By End User – By Pediatrics
  - 8.2.1. By Value (2013 – 2017)
  - 8.2.2. By Value (2018 – 2023)
- 8.3. Global Growth Hormone Deficiency Drugs Market, By End User – By Adult
  - 8.3.1. By Value (2013 – 2017)
  - 8.3.2. By Value (2018 – 2023)

### **9. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET: REGIONAL**

## **ANALYSIS**

### 9.1. North America Growth Hormone Deficiency Drugs Market

9.1.1. By Value (2013 – 2017)

9.1.2. By Value (2018 – 2023)

### 9.2. Europe Growth Hormone Deficiency Drugs Market

9.2.1. By Value (2013 – 2017)

9.2.2. By Value (2018 – 2023)

### 9.3. ROW Growth Hormone Deficiency Drugs Market

9.3.1. By Value (2013 – 2017)

9.3.2. By Value (2018 – 2023)

## **10. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET: COUNTRY ANALYSIS**

### 10.1. U.S. Growth Hormone Deficiency Drugs Market

10.1.1. By Value (2013 – 2017)

10.1.2. By Value (2018 – 2023)

### 10.2. U.K. Growth Hormone Deficiency Drugs Market

10.2.1. By Value (2013 – 2017)

10.2.2. By Value (2018 – 2023)

### 10.3. France Growth Hormone Deficiency Drugs Market

10.3.1. By Value (2013 – 2017)

10.3.2. By Value (2018 – 2023)

### 10.4. Germany Growth Hormone Deficiency Drugs Market

10.4.1. By Value (2013 – 2017)

10.4.2. By Value (2018 – 2023)

### 10.5. Spain Growth Hormone Deficiency Drugs Market

10.5.1. By Value (2013 – 2017)

10.5.2. By Value (2018 – 2023)

### 10.6. Japan Growth Hormone Deficiency Drugs Market

10.6.1. By Value (2013 – 2017)

10.6.2. By Value (2018 – 2023)

## **11. HUMAN GROWTH HORMONE DEFICIENCY (HGHD) PIPELINE DRUGS COVERAGE**

### 11.1. hGHD Pipeline Drugs – TransCon-hGH

11.1.1. Description

- 11.1.2. Regulatory Milestones
- 11.1.3. Advantages & Disadvantages
- 11.1.4. Product Profile & Launch Date
- 11.1.5. Clinical Trials and Status
- 11.1.6. Pivotal Clinical Trials and Results
- 11.1.7. TransCon-hGH – Global Market Potential
- 11.1.8. TransCon-hGH – Global Market Potential
- 11.2. hGHD Pipeline Drugs – Somapacitan
  - 11.2.1. Description
  - 11.2.2. Regulatory Milestones
  - 11.2.3. Advantages & Disadvantages
  - 11.2.4. Product Profile & Launch Date
  - 11.2.5. Clinical Trials and Status
  - 11.2.6. Pivotal Clinical Trials and Results
  - 11.2.7. Somapacitan – Global Market Potential
  - 11.2.8. Somapacitan – 7Ps Analysis
- 11.3. hGHD Pipeline Drugs – Somavaratan
  - 11.3.1. Description
  - 11.3.2. Regulatory Milestones
  - 11.3.3. Advantages & Disadvantages
  - 11.3.4. Product Profile & Launch Date
  - 11.3.5. Clinical Trials and Status
  - 11.3.6. Pivotal Clinical Trials and Results
  - 11.3.7. Somavaratan – Global Market Potential
  - 11.3.8. Somavaratan – 7Ps Analysis
- 11.4. hGHD Pipeline Drugs – Somatrogen/ Lagova
  - 11.4.1. Description
  - 11.4.2. Regulatory Milestones
  - 11.4.3. Advantages & Disadvantages
  - 11.4.4. Product Profile & Launch Date
  - 11.4.5. Clinical Trials and Status
  - 11.4.6. Pivotal Clinical Trials and Results
  - 11.4.7. Somatrogen/ Lagova – Global Market Potential
  - 11.4.8. Somatrogen/ Lagova – 7Ps Analysis
- 11.5. Competitive Landscape

## **12. COMPANY PROFILES**

### **12.1. Ascendis Pharma A/S**

- 12.2. Novo Nordisk A/S
- 12.3. Versartis Inc.
- 12.4. Opko Health, Inc.
- 12.5. Pfizer Inc

## List Of Figures

### LIST OF FIGURES

Figure 1: Global Growth Hormones Drugs Market Size, By value, 2013-2017 (USD Billion)

Figure 2: Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)

Figure 3: Global Growth Hormones Market Share 2017

Figure 4: Sales of Growth Hormones, By Value, 2014-2017

Figure 5: Global Growth Hormone Market Share, 2017 (%)

Figure 6: Global Growth Hormones Deficiency Drugs Market Size, By value, 2013-2017 (USD Billion)

Figure 7: Global Growth Hormones Deficiency Drugs Market Size, By value, 2018-2023 (USD Billion)

Figure 8: Global Growth Hormone Market 2017

Figure 9: Global Growth Hormone Market 2028

Figure 10: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)

Figure 11: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)

Figure 12: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2013-2017 (USD Billion)

Figure 13: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2018-2023 (USD Billion)

Figure 14: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2013-2017 (USD Billion)

Figure 15: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2018-2023 (USD Billion)

Figure 16: North America Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 17: Europe Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 18: ROW Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 19: US Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 20: U.S. Per Capita Health Expenditure, 2012-2016 (USD)

Figure 21: U.S Prevalence of Cancer, in cases per 100,000 (2014-2016)



Figure 22: UK Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 23: France Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 24: France Per Capita Healthcare Expenditure (USD)

Figure 25: France Prevalence of Cancer, in cases per 100,000 (2014-2016)

Figure 26: Germany Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 27: Germany Healthcare Expenditure (USD Billion, 2014-2017)

Figure 28: Germany Prevalence of Cancer, in cases per 100,000 (2014-2016)

Figure 29: Spain Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 30: Japan Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)

Figure 31: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment

Figure 32: Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment

Figure 33: Dose Proportional IGF-1 Elevation Observed into the Normal Range

Figure 34: Comparable hGH levels for TransCon Growth Hormone and Daily hGH

Figure 35: Global TransCon hGH Market Size, By Value, Forecast, 2020-2023 (USD million)

Figure 36: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment

Figure 37: Global Somapacitan (NN8640) Market Size, By Value, Forecast, 2020-2023 (USD million)

Figure 38: Height Velocity at 12 months in ITT and PP groups

Figure 39: Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)

Figure 40: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment

Figure 41: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment

Figure 42: Global Somatrogon (Lagova) Market Size, By Value, Forecast, 2020-2023 (USD million)

Figure 43: Ascendis Pharma Company Net Sales, By Value, in million €

Figure 44: Novo Nordisk Company Net Sales, By Value, in million DKK

Figure 45: Norditropin® net sales, by value, in million DKK

Figure 46: Pfizer Company Revenue, By Value, in million USD

Figure 47: Genotropin net sales, by value, in million USD

## List Of Tables

### LIST OF TABLES

Table A: Upcoming Drugs in the market of Growth Hormone Deficiency and their Clinical Status from 2016 - 2020

## I would like to order

Product name: Global Human Growth Hormone Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023

Product link: <https://marketpublishers.com/r/G33C1CDAF3FEN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G33C1CDAF3FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

